ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ascendis Pharma A/S (ASND) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong bullish technical indicators, positive analyst sentiment with raised price targets, and a promising growth outlook driven by its product pipeline and market expansion potential. While hedge funds are selling, insider sentiment remains neutral, and there are no significant negative catalysts to deter investment.
The technical indicators for ASND are bullish. The MACD is above 0 and positively contracting, the RSI is neutral at 53.5, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot level of 224.893, with resistance levels at 234.825 and 240.961, suggesting room for upward movement.
Analysts have raised price targets significantly, with the highest target at $330, reflecting strong confidence in the company's growth potential.
Management expects FDA approval for TransCon CNP by February 28, 2026, and a timely launch afterward, which could drive significant revenue growth.
Yorvipath adoption is expected to grow steadily, with low discontinuation rates and underpenetrated markets in the U.S. and EU.
Hedge funds are selling, with a 565.41% increase in selling activity over the last quarter.
The company reported a net loss of -$33.56M in Q4 2025, which might raise concerns for some investors.
In Q4 2025, Ascendis Pharma reported revenue of $247.5M, with no year-over-year growth. Net income was -$33.56M, and EPS was -$0.55. However, the gross margin remained strong at 90.47%, indicating efficient cost management.
Analysts have a positive outlook on ASND, with multiple firms raising price targets recently. The targets range from $250 to $330, and ratings include Buy, Overweight, and Outperform. Analysts highlight strong growth potential in Yorvipath adoption and the upcoming FDA approval of TransCon CNP as key drivers.
